Share This:
https://ntp.niehs.nih.gov/go/18973

Target Organs and Levels of Evidence for TR-538

Toxicology and Carcinogenesis Studies of Methyl Isobutyl Ketone (CASRN 108-10-1) in F344/N Rats and B6C3F1 Mice (Inhalation Studies)

Chemical (Study Title)
CASRN
Peer Review DatePrimary UsesRoute/Exposure LevelsStudy Laboratory
Methyl isobutyl ketone
108-10-1
09/27/2005Used as a denaturant for rubbing alcohol; as a solvent for paints, varnishes, nitrocellulose, lacquers, and protective coatings; in industrial extraction processes; in dry-cleaning preparations; and in the synthesis of methyl isobutyl carbinol. Associated with tobacco: reported either as a natural component of tobacco, pyrolysis product (in tobacco smoke), or additive for one or more types of tobacco products.Inhalation
R&M: 0, 450, 900, OR 1800 PPM
Battelle Northwest Laboratory

Levels of Evidence

Male Rats: Some Evidence
TypeOrgan/Tissue (Lesion)
Neoplastic Lesions
  • Kidney Tubular Cell: ADENOMA (STANDARD EVALUATION - 0/50 0/50 2/50 3/50; STANDARD AND EXTENDED EVAULATION COMBINED - 2/50 3/50 3/50 10/50); CARCINOMA (STANDARD EVALUATION - 0/50 1/50 0/50 2/50); ADENOMA OR CARCINOMA (COMBINED) (STANDARD EVAULATION - 0/50 1/50 2/50 4/50; STANDARD AND EXTENDED EVALUATION - 2/50 4/50 3/50 11/50)
May Have Been Related
  • Hematopoietic System: MONONUCLEAR CELL LEUKEMIA 25/50 26/50 32/50 35/50
Non-Neoplastic Lesions
  • KIDNEY: TUBULE HYPERPLASIA; INCREASED SEVERITY OF NEPHROPATHY; PELVIS TRANSITIONAL EPITHELIAL HYPERPLASIA; PAPILLA MINERALIZATION
  • ADRENAL GLAND: ADRENAL MEDULLA HYPERPLASIA
Female Rats: Equivocal Evidence
TypeOrgan/Tissue (Lesion)
Neoplastic Lesions
  • Kidney Mesenchymal Cell: TUMOR MALIGNANT 0/50 0/50 0/50 2/50
Non-Neoplastic Lesions
  • KIDNEY: NEPHROPATHY
Male Mice: Some Evidence
TypeOrgan/Tissue (Lesion)
Neoplastic Lesions
  • Liver: ADENOMA 17/50 25/50 23/50 34/50 ADENOMA OR CARCINOMA (COMBINED) 27/50 34/50 28/50 37/50
Female Mice: Some Evidence
TypeOrgan/Tissue (Lesion)
Neoplastic Lesions
  • Liver: ADENOMA 13/50 15/50 20/50 23/50 ADENOMA OR CARCINOMA (COMBINED) 17/50 17/50 22/50 27/50